Skip to content

Pharmacological Research

ISSN 1096-1186, 1043-6618

30 papers in the library · 174 citations · publishing 2007-2026

Papers

Sort Most recent Most cited

Therapeutic potential of classic and non-classic psychedelics in neurodevelopmental disorders: Opportunities and challenges

Pharmacological Research August 26, 2026 Mattia Giovenzana, Noemi Nicosia, Stefano Spinosa et al.

Neurodevelopmental disorders (NDDs) comprise a heterogeneous group of conditions arising from altered brain development and leading to impairments in social, cognitive, emotional, and motor domains. Clinical manifestations are highly variable in severity and symptom profile, reflecting the complex and multifactorial etiology of NDDs. Available treatments are limited to early behavioral...

Effect of intraoperative esketamine on moderate-to-severe depressive symptoms in major surgery patients: A randomized clinical trial.

Pharmacological Research July 1, 2026 Yang Zhou, Wanchen Sun, Yuxuan Fu et al.

Perioperative depressive symptoms (PDSs) are common among patients who undergo major surgery and can lead to worse clinical outcomes. Esketamine has been reported to alleviate PDSs in patients undergoing certain types of surgery. However, there is a lack of evidence from large-scale, multisurgery studies to support its therapeutic effects in individuals with preexisting moderate-to-severe PDSs....

Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and type 2 diabetes via 5-HT2B receptor-dependent mechanisms

Pharmacological Research December 29, 2025 Martina Colognesi, Daniela Gabbia, Anna Signor et al. 3 citations

The therapeutic potential of low, non-psychedelic doses of psilocybin, a fungal tryptamine alkaloid, was investigated in metabolic disorders including obesity, type 2 diabetes mellitus (T2DM), and liver steatosis. Mice fed a high-fat/high-fructose diet received chronic treatment with psilocybin (0.05 mg/kg) for 12 weeks. Body weight, liver histology, insulin sensitivity, and skeletal muscle...

Effect of esketamine on postoperative depression and anxiety in patients undergoing cardiac valve surgery: a randomised, placebo-controlled, double-blinded clinical trial.

Pharmacological Research November 22, 2025 Zhuo-Ning Zhang, Xin-Yu Hao, Chen Cai et al. 5 citations

This randomized, double-blind, parallel-group trial evaluated the efficacy of a single intravenous dose of esketamine (0.3mg/kg) administered at anesthesia induction in reducing postoperative depression and anxiety among patients undergoing cardiac valve surgery. A total of 142 patients from three centers were randomly assigned to receive esketamine or saline. The primary outcomes were the...

DOI: 10.1016/j.phrs.2025.108047 (opens in new tab) Full text (opens in new tab) Cardiac valve surgery Esketamine esketamine Postoperative depression Postoperative anxiety +5

All roads lead to glutamate: NMDA and AMPA receptors as targets for rapid-acting antidepressants.

Pharmacological Research October 1, 2025 Florian Freudenberg, Christine Reif-Leonhard, Gerard R Dawson et al.

Treatment-resistant depression (TRD) represents a major clinical challenge. Affecting about 30 % of major depressive disorder (MDD) patients, effective treatments for TRD are urgently needed. While depression research and antidepressant (AD) development have long centred on monoaminergic targets, research over the past 35 years has increasingly explored glutamatergic mechanisms. Here we present...

Effect of ketamine and esketamine on RNA expression and its relevance for depression: a systematic review.

Pharmacological Research July 31, 2025 C. Pisanu, R. Carvalho Silva, Mattia Meattini et al. 6 citations

Treatment-resistant depression (TRD) remains a challenge in psychiatry, necessitating novel therapeutic strategies beyond traditional monoaminergic antidepressants. Ketamine and its S-enantiomer esketamine have demonstrated rapid and robust antidepressant effects in TRD, probably through mechanisms involving glutamatergic modulation, neuroplasticity, and anti-inflammatory properties. However,...

The pharmacological treatment of anxiety in people with eating disorders: A systematic review

Pharmacological Research May 14, 2025 Rebecca Morris, Janet Treasure, Hubertus Himmerich et al. 4 citations

People with eating disorders experience high rates of psychiatric comorbidities, including anxiety disorders such as generalised anxiety disorder, social anxiety disorder and specific phobias. Anxiety can influence the prognosis of an eating disorder, by worsening symptoms, and acting as a barrier to treatment. Therefore, targeting treatment efforts towards anxiety may improve eating disorder...

DOI: 10.1016/j.phrs.2025.107782 (opens in new tab) Anxiety Eating disorders Psychotherapist Clinical psychology +1

IUPHAR Article: Psilocybin induces long-lasting effects via 5-HT2A receptors in mouse models of chronic pain.

Pharmacological Research May 1, 2025 Eda Koseli, Belle Buzzi, Torin Honaker et al. 11 citations

Chronic pain is a debilitating disease with current treatments lacking efficacy and safety, therefore discovery of new treatments is crucial. Initial studies suggest that psychedelics may be feasible for targeting pain, however clinical and preclinical controlled studies are necessary to further investigate that possibility. In this study we assessed the effects of two classical psychedelics...

DOI: 10.1016/j.phrs.2025.107699 (opens in new tab) Full text (opens in new tab) Psilocybin magic mushrooms Hallucinogenic mushrooms Long-term pain Neuroscience brain research +6

Muscarinic cannabinoid suppression of excitation, a novel form of coincidence detection.

Pharmacological Research February 1, 2025 Michaela Dvorakova, Ken Mackie, Alex Straiker 2 citations

Δ9-tetrahydrocannabinol (THC), the chief psychoactive ingredient of cannabis, acts in the brain primarily via cannabinoid CB1 receptors. These receptors are implicated in several forms of synaptic plasticity - depolarization-induced suppression of excitation (DSE), metabotropic suppression of excitation (MSE), long term depression (LTD) and activation-dependent desensitization. Cultured...

DOI: 10.1016/j.phrs.2025.107606 (opens in new tab) Full text (opens in new tab) Synaptic plasticity Autaptic hippocampal neurons Cb1 receptor M3/m5 muscarinic receptors

Modulation of the endocannabinoid system by (S)-ketamine in an animal model of depression.

Pharmacological Research 2025 Nicole R Silva, Shokouh Arjmand, Luana B Domingos et al. 6 citations

Ketamine (KET) is recognized as rapid-acting antidepressant, but its mechanisms of action remain elusive. Considering the role of endocannabinoids (eCB) in stress and depression, we investigated if S-KET antidepressant effects involve the regulation of the eCB system using an established rat model of depression based on selective breeding: the Flinders Sensitive Line (FSL) and their controls,...

DOI: 10.1016/j.phrs.2024.107545 (opens in new tab) Full text (opens in new tab) Esketamine Flinders sensitive line Lipidome Ketamine therapy s-ketamine +4

Mind over matter: the microbial mindscapes of psychedelics and the gut-brain axis.

Pharmacological Research September 1, 2024 Giorgia Caspani, Simon Ruffell, WaiFung Tsang et al. 13 citations

Psychedelics have emerged as promising therapeutics for several psychiatric disorders. Hypotheses around their mechanisms have revolved around their partial agonism at the serotonin 2 A receptor, leading to enhanced neuroplasticity and brain connectivity changes that underlie positive mindset shifts. However, these accounts fail to recognise that the gut microbiota, acting via the gut-brain...

Dynamic regulation of phosphorylation of NMDA receptor GluN2B subunit tyrosine residues mediates ketamine rapid antidepressant effects.

Pharmacological Research July 1, 2024 Ke Wang, Xuan Tan, Kai-Mo Ding et al. 5 citations

The rapid antidepressant effects of ketamine depend on the N-methyl-D-aspartate (NMDA) receptor containing 2B subunit (NR2B), whose function is influenced by its phosphorylated regulation and distribution within and outside synapses. It remains unclear if ketamine's rapid onset of antidepressant effects relies on the dynamic phosphorylated regulation of NR2B within and outside synapses. Here,...

DOI: 10.1016/j.phrs.2024.107236 (opens in new tab) Full text (opens in new tab) Dephosphorylation Dynamic phosphorylation Nr2b Rapid antidepressant effects +5

Novel rapid treatment options for adolescent depression.

Pharmacological Research March 1, 2024 Sandra Ledesma-Corvi, Jordi Jornet-Plaza, Laura Gálvez-melero et al. 22 citations

There is an urgent need for novel fast-acting antidepressants for adolescent treatment-resistant depression and/or suicidal risk, since the selective serotonin reuptake inhibitors that are clinically approved for that age (i.e., fluoxetine or escitalopram) take weeks to work. In this context, one of the main research lines of our group is to characterize at the preclinical level novel...

DOI: 10.1016/j.phrs.2024.107085 (opens in new tab) Full text (opens in new tab) Depression Adolescence Fast-acting antidepressants Sex differences +1

IUPHAR-review: The integration of classic psychedelics into current substance use disorder treatment models.

Pharmacological Research 2024 David B. Yaden, Andrea P Berghella, Peter S. Hendricks et al. 12 citations

Substance use disorders (SUDs) have an enormous impact on public health. With classic psychedelic-assisted therapies showing initial promise in treating multiple SUDs, it is possible that these treatments will become legally available options for patients with SUDs in the future. This article highlights how classic psychedelic-assisted therapies might be integrated into current clinical...

Molecular mechanisms of rapid-acting antidepressants: New perspectives for developing antidepressants

Pharmacological Research June 26, 2023 Tao Chen, Ling Cheng, Jingwen Ma et al. 48 citations

Major depressive disorder (MDD) is a chronic relapsing psychiatric disorder. Conventional antidepressants usually require several weeks of continuous administration to exert clinically significant therapeutic effects, while about two-thirds of the patients are prone to relapse of symptoms or are completely ineffective in antidepressant treatment. The recent success of the N-methyl-D-aspartic...

IUPHAR - invited review - Ibogaine - A legacy within the current renaissance of psychedelic therapy.

Pharmacological Research April 1, 2023 Deborah C. Mash 37 citations

Ibogaine is a powerful psychoactive substance that not only alters perception, mood and affect, but also stops addictive behaviors. Ibogaine has a very long history of ethnobotanical use in low doses to combat fatigue, hunger and thirst and, in high doses as a sacrament in African ritual contexts. In the 1960's, American and European self-help groups provided public testimonials that a single...

Cannabis induced psychosis: a systematic review on the role of genetic polymorphisms.

Pharmacological Research May 1, 2022 C. Carvalho, M. Vieira-Coelho

OBJECTIVE Cannabis sativa is a recreational drug commonly consumed in Europe and is getting popularity for both recreational and therapeutic use. In some individuals, the use of cannabis leads to psychotic disorders. This systematic review summarizes the current evidence linking genetic polymorphisms and inter-individual susceptibility to psychosis induced by cannabis. METHOD Studies published...

Similarities and differences upon binding of naturally occurring Δ9-tetrahydrocannabinol-derivatives to cannabinoid CB1 and CB2 receptors.

Pharmacological Research December 2021 Iu Raïch, Rafael Rivas-Santisteban, Alejandro Lillo et al.

We have here assessed, using Δ9-tetrahydrocannabinol (Δ9-THC) for comparison, the effect of Δ9-tetrahydrocannabinolic acid (Δ9-THCA) and of Δ9-tetrahydrocannabivarin (Δ9-THCV) that is mediated by human versions of CB1, CB2, and CB1-CB2 receptor functional units, expressed in a heterologous system. Binding to the CB1 and CB2 receptors was addressed in living cells by means of a homogeneous...

DOI: 10.1016/j.phrs.2021.105970 (opens in new tab) Full text (opens in new tab) Bitopic drug Cb1-cb2 receptor heteromers Cannabis sativa l Exosite +2

Phytocannabinoids and schizophrenia: Focus on adolescence as a critical window of enhanced vulnerability and opportunity for treatment.

Pharmacological Research December 1, 2021 Tibor Stark, Serena di Martino, Filippo Drago et al.

The recent shift in socio-political debates and growing liberalization of Cannabis use across the globe has raised concern regarding its impact on vulnerable populations such as adolescents. Concurrent with declining perception of Cannabis harms, more adolescents are using it daily in several countries and consuming marijuana strains with high content of psychotropic delta...

Crosstalk between the transcriptional regulation of dopamine D2 and cannabinoid CB1 receptors in schizophrenia: Analyses in patients and in perinatal Δ9-tetrahydrocannabinol-exposed rats.

Pharmacological Research February 2021 Martina di Bartolomeo, Tibor Stark, Oriana Maria Maurel et al.

Perinatal exposure to Δ9-tetrahydrocannabinol (THC) affects brain development and might increase the incidence of psychopathology later in life, which seems to be related to a dysregulation of endocannabinoid and/or dopaminergic systems. We here evaluated the transcriptional regulation of the genes encoding for the cannabinoid CB1 receptor (Cnr1) and the dopamine D2 receptor (Drd2) in perinatal...

Autophagy inhibition plays a protective role against 3, 4‐methylenedioxymethamphetamine (MDMA)‐induced loss of serotonin transporters and depressive‐like behaviors in rats

Pharmacological Research February 28, 2019 Jui-Hu Shih, Chuang-Hsin Chiu, Kuo-Hsing Ma et al.

Graphical abstract Figure. No Caption available. Abstract The 3,4‐methylenedioxymethamphetamine (MDMA) is a popular recreational drug, which ultimately leads to serotonergic (5‐HT) neurotoxicity and psychiatric disorders. Previous in vitro studies have consistently demonstrated that MDMA provokes autophagic activation, as well as damage of 5‐HT axons and nerve fibers. So far, whether autophagy,...

Cannabidiol in medical marijuana: Research vistas and potential opportunities.

Pharmacological Research July 2017 Carola Rong, Yena Lee, Nicole E Carmona et al.

The high and increasing prevalence of medical marijuana consumption in the general population invites the need for quality evidence regarding its safety and efficacy. Herein, we synthesize extant literature pertaining to the phytocannabinoid cannabidiol (CBD) and its brain effects. The principle phytocannabinoid Δ9-tetrahydrocannabinol (Δ9-THC) and CBD are the major pharmacologically active...

Opioid gene expression changes and post-translational histone modifications at promoter regions in the rat nucleus accumbens after acute and repeated 3,4-methylenedioxy-methamphetamine (MDMA) exposure.

Pharmacological Research December 2016 Francesca Felicia Caputi, Martina Palmisano, Lucia Carboni et al.

The recreational drug of abuse 3,4-methylenedioxymethamphetamine (MDMA) has been shown to produce neurotoxic damage and long-lasting changes in several brain areas. In addition to the involvement of serotoninergic and dopaminergic systems, little information exists about the contribution of nociceptin/orphaninFQ (N/OFQ)-NOP and dynorphin (DYN)-KOP systems in neuronal adaptations evoked by MDMA....

The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT1A, D2 and TAAR1 receptors.

Pharmacological Research November 2016 Danilo de Gregorio, Luca Posa, Rafael Ochoa-Sanchez et al.

d-lysergic diethylamide (LSD) is a hallucinogenic drug that interacts with the serotonin (5-HT) system binding to 5-HT1 and 5-HT2 receptors. Little is known about its potential interactions with the dopamine (DA) neurons of the ventral tegmental area (VTA). Using in-vivo electrophysiology in male adult rats, we evaluated the effects of cumulative doses of LSD on VTA DA neuronal activity,...

DOI: 10.1016/j.phrs.2016.08.022 (opens in new tab) Full text (opens in new tab) Serotonin 8-oh-dpat pubchem cid Apomorphine pubchem cid Dopamine +6

Long-term hippocampal glutamate synapse and astrocyte dysfunctions underlying the altered phenotype induced by adolescent THC treatment in male rats.

Pharmacological Research September 2016 Erica Zamberletti, Marina Gabaglio, Massimo Grilli et al.

Cannabis use has been frequently associated with sex-dependent effects on brain and behavior. We previously demonstrated that adult female rats exposed to delta-9-tetrahydrocannabinol (THC) during adolescence develop long-term alterations in cognitive performances and emotional reactivity, whereas preliminary evidence suggests the presence of a different phenotype in male rats. To thoroughly...

DOI: 10.1016/j.phrs.2016.07.008 (opens in new tab) Full text (opens in new tab) Adolescence Astrocytes Behavior Delta-9-tetrahydrocannabinol +2